Prelude Therapeutics Management
Management criteria checks 4/4
Prelude Therapeutics' CEO is Kris Vaddi, appointed in Feb 2016, has a tenure of 10.42 years. total yearly compensation is $1.35M, comprised of 45.7% salary and 54.3% bonuses, including company stock and options. directly owns 3.14% of the company’s shares, worth $15.31M. The average tenure of the management team and the board of directors is 4.5 years and 6.2 years respectively.
Key information
Kris Vaddi
Chief executive officer
US$1.3m
Total compensation
| CEO salary percentage | 45.66% |
| CEO tenure | 10.4yrs |
| CEO ownership | 3.1% |
| Management average tenure | 4.5yrs |
| Board average tenure | 6.2yrs |
Recent management updates
Recent updates
Narrative Update • Jun 26
PRLD: Metastatic Breast Cancer Program Will Drive Upside From Early-Stage Platform
The analyst price target for Prelude Therapeutics has been revised higher from $5 to $10, as analysts point to the company's differentiated approach in metastatic breast cancer and the large addressable market opportunity cited in recent research coverage. Analyst Commentary Recent research on Prelude Therapeutics highlights growing interest in the company’s approach to metastatic breast cancer and the potential market it is targeting.Analysis Article • May 16
Prelude Therapeutics Incorporated (NASDAQ:PRLD) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
Shareholders might have noticed that Prelude Therapeutics Incorporated ( NASDAQ:PRLD ) filed its first-quarter result...
New Narrative • Mar 06
Future Returns Will Depend On JAK2 Program Validation And Incyte Milestones
Catalysts About Prelude Therapeutics Prelude Therapeutics is a clinical stage oncology company focused on discovering and developing precision cancer medicines. What are the underlying business or industry changes driving this perspective?Analysis Article • Dec 03
Prelude Therapeutics Incorporated's (NASDAQ:PRLD) 66% Share Price Plunge Could Signal Some Risk
Prelude Therapeutics Incorporated ( NASDAQ:PRLD ) shares have retraced a considerable 66% in the last month, reversing...Seeking Alpha • Nov 03
Prelude Therapeutics: A Subtle Shift In Pipeline Underscores Funding Challenges
Summary Prelude Therapeutics continues to explore the SMARCA2 anticancer approach, with no major hiccups disclosed to date. A strategic shift from their main pipeline contender raises concerns about data not yet disclosed, however. PRLD's funding situation is also in doubt, as they will find themselves needing to raise cash in the coming months. An upcoming ASH presentation could also shed some light on the next steps for two preclinical projects in myeloproliferative neoplasms. Read the full article on Seeking AlphaAnalysis Article • Jun 16
Prelude Therapeutics (NASDAQ:PRLD) Will Have To Spend Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, although...Analysis Article • Mar 17
We Think Prelude Therapeutics (NASDAQ:PRLD) Needs To Drive Business Growth Carefully
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Analysis Article • Sep 16
We're Keeping An Eye On Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Rate
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Analysis Article • May 09
We Think Prelude Therapeutics (NASDAQ:PRLD) Needs To Drive Business Growth Carefully
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Seeking Alpha • Feb 03
Prelude Therapeutics: Scientifically Interesting Oncology Company With Preclinical Data
Summary Prelude Therapeutics once produced positive clinical data from a now abandoned program. The company's current lead candidates are PRT3789, a SMARCA2 inhibitor, and PRT2527, a CDK9 inhibitor, both in phase 1 trials. Both programs have early preclinical data and look scientifically interesting. However, they are too early to merit an investment right now, although they bear watching. Read the full article on Seeking AlphaAnalysis Article • Sep 17
Here's Why We're Watching Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Analysis Article • May 28
We Think Prelude Therapeutics (NASDAQ:PRLD) Needs To Drive Business Growth Carefully
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Analysis Article • Jan 28
Here's Why We're Not Too Worried About Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Analysis Article • Oct 27
We're Hopeful That Prelude Therapeutics (NASDAQ:PRLD) Will Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, although...Seeking Alpha • Oct 18
Prelude wins FDA clearance to start Phase 1 trial for cancer candidate
Prelude Therapeutics (NASDAQ:PRLD), an oncology-focused biotech, announced Tuesday that the FDA cleared its Investigational New Drug Application (IND) for PRT3789 allowing the company to start a Phase 1 trial for the antitumor agent. A protein degrader targeted at SMARCA2 (BRM) mutations in cancer tissue, PRT3789, has demonstrated antitumor activity in preclinical models at well-tolerated doses, the company said. “Clearance of the IND for PRT3789 represents a major milestone for Prelude Therapeutics, as we advance our first-in-class SMARCA2 protein degrader from discovery to the clinic,” Dr. Peggy Scherle, Chief Scientific Officer of Prelude (PRLD), noted. The Phase 1 trial for PRT3789 is designed to enroll patients with advanced solid tumors harboring SMARCA4. The dosing is expected to start in Q1 2023. PRLD awaits multiple catalysts in its clinical programs this year.Seeking Alpha • Sep 09
Prelude downgraded at Morgan Stanley ahead of key update
Prelude Therapeutics (NASDAQ:PRLD) inched lower on Friday after Morgan Stanley downgraded the cancer-focused biotech to Equal Weight from Overweight as the company plans to disclose key steps forward for its PRMT5 program, including the solid tumor candidate PRT811 in H2 2022. The analysts see upside potential as PRLD remains on track to report early findings from its MCL1 inhibitor program and CDK9 inhibitor program during the second half of 2022. However, they see better opportunities elsewhere in the coverage noting uncertainty over the path forward for PRT811. Morgan Stanley lowers the probability of success for PRT811 in GBM, solid tumors, and myeloid malignancies to 20% from 25%, in line with the range it usually uses for Phase 1 assets, and trims the price target for PRLD to $11 from $19. Early this year, PRLD decided to drop the development of the PRT543 candidate in its PRMT5 program and focus its efforts on PRT811.Analysis Article • Jun 28
We're Not Very Worried About Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Analysis Article • Mar 14
Companies Like Prelude Therapeutics (NASDAQ:PRLD) Are In A Position To Invest In Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Analysis Article • Dec 14
We Think Prelude Therapeutics (NASDAQ:PRLD) Can Afford To Drive Business Growth
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Analysis Article • Jul 05
Companies Like Prelude Therapeutics (NASDAQ:PRLD) Are In A Position To Invest In Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$78m |
| Dec 31 2025 | US$1m | US$615k | -US$99m |
| Sep 30 2025 | n/a | n/a | -US$112m |
| Jun 30 2025 | n/a | n/a | -US$124m |
| Mar 31 2025 | n/a | n/a | -US$128m |
| Dec 31 2024 | US$2m | US$594k | -US$127m |
| Sep 30 2024 | n/a | n/a | -US$132m |
| Jun 30 2024 | n/a | n/a | -US$130m |
| Mar 31 2024 | n/a | n/a | -US$126m |
| Dec 31 2023 | US$3m | US$573k | -US$122m |
| Sep 30 2023 | n/a | n/a | -US$117m |
| Jun 30 2023 | n/a | n/a | -US$117m |
| Mar 31 2023 | n/a | n/a | -US$114m |
| Dec 31 2022 | US$3m | US$558k | -US$115m |
| Sep 30 2022 | n/a | n/a | -US$120m |
| Jun 30 2022 | n/a | n/a | -US$120m |
| Mar 31 2022 | n/a | n/a | -US$120m |
| Dec 31 2021 | US$7m | US$544k | -US$112m |
| Sep 30 2021 | n/a | n/a | -US$98m |
| Jun 30 2021 | n/a | n/a | -US$84m |
| Mar 31 2021 | n/a | n/a | -US$69m |
| Dec 31 2020 | US$12m | US$417k | -US$57m |
| Sep 30 2020 | n/a | n/a | -US$48m |
| Jun 30 2020 | n/a | n/a | -US$38m |
| Mar 31 2020 | n/a | n/a | -US$32m |
| Dec 31 2019 | US$2m | US$315k | -US$28m |
Compensation vs Market: Kris's total compensation ($USD1.35M) is below average for companies of similar size in the US market ($USD2.47M).
Compensation vs Earnings: Kris's compensation has been consistent with company performance over the past year.
CEO
Kris Vaddi (60 yo)
10.4yrs
Tenure
US$1,348,000
Compensation
Dr. Krishna Vaddi, D.V.M., Ph D., also known as Kris, founded Prelude Therapeutics Incorporated and serves as its Chief Executive Officer and Director from February 2016. He has been its Chief Executive Of...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 10.4yrs | US$1.35m | 3.14% $ 15.3m | |
| CFO, Chief Legal Officer & Corporate Secretary | 3.4yrs | US$847.40k | 0.028% $ 134.5k | |
| Chief Scientific Officer | 8.3yrs | US$819.73k | 0.19% $ 911.7k | |
| Senior VP and Head of Strategic Planning & Operations | 4.5yrs | no data | no data | |
| Senior Vice President of Technical Operations | 5.5yrs | no data | no data | |
| Senior Vice President of Investor Relations | 1.5yrs | no data | no data | |
| Chief People Officer | 5.1yrs | no data | no data | |
| Executive VP & Chief Chemistry Officer | 7.3yrs | US$2.63m | 0.48% $ 2.4m | |
| Senior Vice President of Translation Medicine | 4.6yrs | no data | no data | |
| Senior Vice President of Clinical Development | 3.8yrs | no data | no data | |
| Senior Vice President of Clinical Pharmacology | 1.5yrs | no data | no data | |
| Chief Business Officer | 2.3yrs | no data | 0.10% $ 491.0k |
4.5yrs
Average Tenure
57yo
Average Age
Experienced Management: PRLD's management team is considered experienced (4.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 10.4yrs | US$1.35m | 3.14% $ 15.3m | |
| Independent Chairman of the Board | 10yrs | US$102.53k | 0.50% $ 2.5m | |
| Independent Director | 5yrs | US$78.53k | 0% $ 0 | |
| Independent Director | 10.1yrs | US$86.03k | 0% $ 0 | |
| Independent Directors | less than a year | US$77.56k | no data | |
| Independent Director | 6.2yrs | US$194.53k | 0% $ 0 | |
| Independent Directors | 1.1yrs | US$81.57k | no data |
6.2yrs
Average Tenure
60yo
Average Age
Experienced Board: PRLD's board of directors are considered experienced (6.2 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/06 05:50 |
| End of Day Share Price | 2026/07/02 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Prelude Therapeutics Incorporated is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| Reni Benjamin | Citizens JMP Securities, LLC |
| Jason Kolbert | D. Boral Capital LLC. |